Bionano Genomics Earnings Call Highlights Growth, Risks

Bionano Genomics ((BNGO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bionano Genomics’ latest earnings call struck a cautiously optimistic tone, blending clear signs of commercial traction with equally clear reminders of financial fragility. Management highlighted record flow cell demand, expanding consumables revenue, better margins and improved reimbursement, yet also acknowledged choppy software sales, ongoing cash burn and a runway that stretches into 2027 but not yet to profitability.

Revenue Growth and Guidance Reaffirmed

Bionano reported Q1 2026 revenue of $6.7 million, a 4% year-over-year gain that landed at the top end of its guidance range and showed modest but steady growth. Management reaffirmed full-year 2026 revenue guidance of $30 million to $33 million and projected Q2 revenue of $7.5 million to $7.8 million, implying double-digit growth versus the prior year.

Record Flow Cell Unit Sales and Utilization

The company sold 8,178 nanochannel array flow cells in the quarter, a 17% increase from Q1 2025 and the highest first-quarter unit volume in its history. Strikingly, when excluding flow cells tied to new system placements, sales to existing customers jumped 21%, signaling deeper routine use rather than one-off evaluation.

Consumables and Recurring Revenue Momentum

Consumables revenue climbed 20% year over year to $3.9 million, underscoring a shift toward more recurring, usage-driven sales as installed systems ramp. Other revenue rose 36% to $1.6 million, further tilting the mix toward ongoing revenue streams that can smooth out volatility and improve predictability over time.

Improving Gross Margin and Operational Efficiency

Adjusted gross margin improved to 49% in Q1 2026 from 46% a year earlier, driven by operational efficiencies and a richer contribution from higher-margin consumables and software. Management underscored that margin gains are central to the path toward a more sustainable model, even as overall scale remains limited and operating losses persist.

Meaningful Reimbursement Milestones

Two reimbursement wins effective in Q1 are expected to materially improve test economics and lower adoption barriers for optical genome mapping, or OGM. Payment levels for hematologic malignancy testing rose sharply, while a separate code for constitutional disorders secured a specific rate, giving labs clearer visibility on reimbursement and potential profitability.

Scientific and Clinical Momentum

The company pointed to robust publication activity as validation of OGM’s clinical relevance, with 28 rare disease papers, a sharp increase in samples studied and nearly 2,000 genomes published in the quarter. Notably, studies from major academic centers reported OGM outperforming traditional methods in multiple myeloma and recommended integrating it into standard workflows.

Events and Community Engagement Driving Visibility

Bionano’s 2026 symposium drew more than 1,250 registrants from 73 countries, reflecting growing global interest in its technology. Presentations highlighted large-scale use cases, including plans for thousands of samples per year and high-throughput cancer workflows, suggesting customers are moving from pilot projects toward broader deployment.

Balance Sheet Simplification

The company ended Q1 with $24.7 million in cash, cash equivalents and securities, including restricted amounts, providing liquidity but not yet a long-term safety net. Management said it expects to fully retire its senior secured convertible debt this month, which would simplify the capital structure and reduce financial overhang for investors.

Large Decline in Software Revenue and Lumpy Sales

Software revenue fell 40% year over year to $1.2 million, a sharp contrast to growth in other segments and a reminder of the business’s uneven profile. Executives attributed the decline to a very large software deal booked last year that is covering customer needs across 2025 and 2026, highlighting the risk of quarter-to-quarter swings when relying on big-ticket transactions.

Operating Expense and Continued Cash Burn

Adjusted operating expense rose to $9.1 million from $8.5 million, outpacing revenue and underscoring that Bionano remains meaningfully cash-flow negative. With Q1 revenue still well below operating costs, the company must balance investments in commercialization and R&D against the need to slow burn and extend its financial runway.

Cash Runway and No Near-Term Cash Flow Breakeven

Management reiterated that its $24.7 million of liquidity provides a cash runway into 2027 but cautioned that operating cash flow breakeven is not expected by the end of 2026. Instead, the company is targeting reductions in cash burn toward the back half of 2027, while stopping short of committing to a specific timeline for full breakeven.

Supply Constraints Impacted Production

Supply constraints on flow cell production at the start of the quarter limited the company’s ability to fully meet demand, potentially suppressing near-term revenue. However, management reported that supply began to catch up during Q1 and expects continuing improvement through 2026, which should better align shipments with rising utilization.

Revenue Mix and Predictability Risks

Despite healthy growth in consumables and other recurring lines, Bionano’s reliance on occasional large software deals and prior one-off purchases continues to inject volatility into results. The 40% drop in software revenue this quarter exemplifies that risk, reminding investors that the revenue base is still in transition from early-stage lumpiness to a steadier, usage-driven model.

Forward-Looking Guidance and Outlook

The reaffirmed full-year revenue outlook of $30 million to $33 million and Q2 guidance calling for mid-teens growth show management’s confidence in rising demand, backed by record flow cell sales, higher consumables usage and improving margins. Yet the company’s own commentary on cash burn, lack of near-term breakeven and ongoing supply and revenue-mix challenges underscores that execution over the next several quarters will be critical to sustaining investor confidence.

Bionano’s earnings call painted a picture of a technology platform gaining real-world traction but still operating under tight financial constraints and operational risk. For investors, the key takeaway is a business moving in the right direction on utilization, margins and reimbursement, but one that remains in an early, volatile phase where progress must be weighed carefully against funding needs and execution demands.